MCID: HPT007
MIFTS: 50

Hepatitis E

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Mental diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Hepatitis E

MalaCards integrated aliases for Hepatitis E:

Name: Hepatitis E 12 73 20 54 44 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:4411
MeSH 44 D016751
SNOMED-CT 67 7111000119109
UMLS 70 C0085293

Summaries for Hepatitis E

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis E virus, which is transmitted by ingestion of contaminated food. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom dark urine, has symptom joint pain, and has symptom jaundice.

MalaCards based summary : Hepatitis E is related to hepatitis and hepatitis a, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis E is AMBP (Alpha-1-Microglobulin/Bikunin Precursor), and among its related pathways/superpathways are Measles and IL-2 Pathway. The drugs Aluminum hydroxide and Aluminum sulfate have been mentioned in the context of this disorder. Affiliated tissues include liver, myeloid and kidney, and related phenotypes are endocrine/exocrine gland and immune system

Wikipedia : 73 Hepatitis E is inflammation of the liver caused by infection with the hepatitis E virus (HEV); it is a... more...

Related Diseases for Hepatitis E

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis E via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 469)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.8 TNF IFNG GRB2 GPT F2 DDX58
2 hepatitis a 31.1 TNF TLR3 IFNG GPT F2 ALB
3 hepatic coma 31.1 GPT F2 ALB
4 liver disease 31.0 TNF MIR122 GPT F2 ALB
5 hepatic encephalopathy 30.7 TNF GPT F2 ALB
6 acute kidney failure 30.6 GPT F2 ALB
7 disease by infectious agent 30.5 TNF MIR122 IFNG GPT ALB
8 cholecystitis 30.5 GPT F2 ALB
9 non-a-e hepatitis 30.5 F2 ALB
10 cholangitis 30.5 TNF GPT F2 ALB
11 hepatorenal syndrome 30.4 GPT F2 ALB
12 viral hepatitis 30.4 TNF TLR3 MIR122 IFNL3 IFNG GPT
13 leptospirosis 30.4 TNF IFNG F2
14 scrub typhus 30.3 TNF IFNG GPT
15 gastroenteritis 30.3 TNF IFNG ALB
16 meningoencephalitis 30.3 TNF CD40LG ALB
17 autoimmune hepatitis 30.2 TNF GPT F2 CD40LG ASGR1 ALB
18 acalculous cholecystitis 30.2 GPT F2 ALB
19 acute cholangitis 30.2 GPT F2 ALB
20 hepatitis b 30.2 TNF TLR3 IFNG GPT F2 ASGR1
21 purpura 30.2 TNF IFNG F2
22 deficiency anemia 30.1 TNF HPX GPT F2 ALB
23 hepatitis d 30.1 IFNL3 GPT F2
24 hemolytic anemia 30.1 TNF IFNG HPX F2 CD40LG
25 disseminated intravascular coagulation 30.0 TNF GPT F2
26 myocarditis 30.0 TNF TLR3 IFNG CD40LG
27 hepatitis c virus 30.0 IFNL3 IFNG GRB2 GPT DDX58
28 dengue disease 30.0 TNF IFNG CD40LG
29 exanthem 30.0 TNF IFNG GPT F2 ALB
30 typhoid fever 30.0 TNF IFNG GPT F2 ALB
31 liver cirrhosis 30.0 TNF MIR122 IFNL3 IFNG GPT F2
32 choledocholithiasis 30.0 GPT F2 ALB
33 hepatitis c 30.0 TNF TLR3 MIR122 IFNG GRB2 GPT
34 acute cystitis 29.9 TNF GPT F2 ALB
35 pericardial effusion 29.9 GPT F2 ALB
36 sclerosing cholangitis 29.9 TNF GPT F2 ALB
37 cholangitis, primary sclerosing 29.9 TNF GPT F2 ALB
38 peripheral nervous system disease 29.9 TNF MIR122 IFNG GPT ALB
39 non-alcoholic steatohepatitis 29.9 TNF MIR122 GPT ALB
40 alcoholic hepatitis 29.9 TNF IFNG GPT F2 ALB
41 dysentery 29.9 TNF GPT ALB
42 thrombocytopenia 29.9 TNF IFNG GPT F2 CD40LG ALB
43 japanese encephalitis 29.8 TNF TLR3 ISG15 DDX58
44 biliary atresia 29.8 TLR3 IFNG GPT F2 ALB
45 eclampsia 29.8 TNF F2 ALB
46 plague 29.7 TNF DDX58 ALB
47 newcastle disease 29.7 TNF TLR3 DDX58
48 cryoglobulinemia 29.7 TNF IFNL3 IFNG GPT CD40LG
49 primary biliary cholangitis 29.7 TLR3 MIR122 GPT F2 CD40LG ALB
50 rubella 29.7 TNF TLR3 IFNG DDX58 CD40LG

Graphical network of the top 20 diseases related to Hepatitis E:



Diseases related to Hepatitis E

Symptoms & Phenotypes for Hepatitis E

Symptoms:

12
  • vomiting
  • fatigue
  • fever
  • jaundice
  • abdominal pain
  • dark urine
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

MGI Mouse Phenotypes related to Hepatitis E:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.9 ALB AMBP ASZ1 CD40LG F2 FYN
2 immune system MP:0005387 9.73 ALB ASGR1 CD40LG DDX58 F2 FYN
3 neoplasm MP:0002006 9.17 ALB DDX58 GRB2 IFNG TLR3 TNF

Drugs & Therapeutics for Hepatitis E

Drugs for Hepatitis E (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
2
Aluminum sulfate Approved Phase 4 10043-01-3
3
Ribavirin Approved Phase 4 36791-04-5 37542
4 Anti-Infective Agents Phase 4
5 Antiviral Agents Phase 4
6 Antimetabolites Phase 4
7
Milk thistle Approved, Experimental, Investigational Phase 2, Phase 3 65666-07-1
8
Nicotinamide Approved, Investigational Phase 2, Phase 3 98-92-0 936
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
10
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 83-88-5 493570
11
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 70-16-6, 59-43-8 1130
12
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
13 Immunologic Factors Phase 3
14 Vaccines Phase 3
15 Vitamin B Complex Phase 2, Phase 3
16 Antioxidants Phase 2, Phase 3
17 Protective Agents Phase 2, Phase 3
18 Vitamin B3 Phase 2, Phase 3
19 Folate Phase 2, Phase 3
20 silymarin Phase 2, Phase 3
21 Thiamin Phase 2, Phase 3
22 Vitamins Phase 2, Phase 3
23 Vitamin B9 Phase 2, Phase 3
24 Nicotinic Acids Phase 2, Phase 3
25 Vitamin B2 Phase 2, Phase 3
26
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
27 Liver Extracts Phase 2
28 Pharmaceutical Solutions Phase 1

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 A Study on Immunogenicity of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® Using Accelerated Vaccination Schedule in Adults (Aged Over 18 Years) Completed NCT03168412 Phase 4
2 An Effectiveness Trial (Phase IV) to Evaluate Protection of Pregnant Women by Hepatitis E Virus (HEV) Vaccine in Bangladesh and Risk Factors for Severe HEV Infection. Completed NCT02759991 Phase 4 Hecolin;Hepa-B
3 Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) Coadministration With Recombinant Hepatitis B Vaccine Completed NCT02584543 Phase 4
4 Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years Completed NCT02417597 Phase 4
5 Evaluation of Safety and Immunogenicity of Recombinant (E. Coli) Hepatitis E Vaccine(Hecolin®) in Seniors Aged Over 65 Years Completed NCT02189603 Phase 4
6 An Open, Pared Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® in the Chronic Hepatitis B Patients on the Clinical Stability .( Aged 30 Years or Over) Completed NCT02964910 Phase 4
7 An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency Completed NCT03365921 Phase 4
8 Randomized Study of Two Treatment Strategies With Ribavirin for Chronic Hepatitis E and Severe Acute Forms Terminated NCT02558114 Phase 4 Ribavirin
9 A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine Completed NCT01014845 Phase 3
10 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Completed NCT01735006 Phase 3
11 A Multicentre, Double-blind, Randomized, Placebo-controlled, Phase II/III Study to Evaluate the Safety and Efficacy of 280 mg and 420 mg Silymarin TID (Legalon® Capsules) Administered for Four Weeks in Subjects With Acute Viral Hepatitis With a Four Week Follow-up Period Terminated NCT00755950 Phase 2, Phase 3
12 A Double Blind Placebo Controlled Randomized Trial of Ribavirin in Patients With Acute on Chronic Liver Failure Due to Hepatitis E Virus Unknown status NCT01698723 Phase 2 Ribavirin;Placebo
13 HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE) Completed NCT03282474 Phase 2 Sofosbuvir
14 A Phase II, Prospective, Randomized, Double-blind, Placebo Controlled, Field Efficacy Trial of a Candidate Hepatitis E Vaccine in Nepal. Completed NCT00287469 Phase 2
15 A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years Active, not recruiting NCT02710851 Phase 2
16 A Phase Ib Single Center, Randomized, Blinding, Parallel-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Hepatitis E Vaccine in Healthy Adults Aged 16 to 65 Years Old in China Completed NCT02603055 Phase 1
17 A Phase 1, Double-Blinded, Placebo Controlled, Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of HEV-239 (Hecolin(R)) in a Healthy US Adult Population Completed NCT03827395 Phase 1
18 Hepatitis E Infection : Emergence Mechanisms in North-Eastern France of Polymorphic Clinical Forms. Unknown status NCT03524014
19 The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors, a Multicenter, Comparative, Cross-sectional Study Unknown status NCT02419625
20 Hepatitis E Virus Infection Among Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver Unknown status NCT03488589
21 Hepatitis E Virus Infection in Pediatric Transplantation, a Prevalence Study Unknown status NCT02809885
22 Observational Study on Seroprevalence of Hepatitis E Infection in Healthy Blood Donors in the Canton Ticino Completed NCT03601221
23 Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection Completed NCT01090232
24 Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients Completed NCT02645955
25 Seroprevalence of Hepatitis E in The Organ Transplant Subjects Completed NCT02190253
26 Morbidity and Mortality of Hepatitis E Virus Infections in Belgium 2010-2018 Completed NCT04670419
27 Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb): a Prospective Cohort Study Completed NCT02847507
28 Role of Cytokines in Hepatitis E Virus Infection During Pregnancy Completed NCT01062321

Search NIH Clinical Center for Hepatitis E

Cochrane evidence based reviews: hepatitis e

Genetic Tests for Hepatitis E

Anatomical Context for Hepatitis E

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis E:

19
Liver

MalaCards organs/tissues related to Hepatitis E:

40
Liver, Myeloid, Kidney, Brain, Bone, Bone Marrow, T Cells

Publications for Hepatitis E

Articles related to Hepatitis E:

(show top 50) (show all 5399)
# Title Authors PMID Year
1
Value of hepatitis E virus detection by cell culture compared with nested PCR and serological studies by IgM and IgG. 54 61
19374667 2009
2
A novel mycovirus that is related to the human pathogen hepatitis E virus and rubi-like viruses. 54 61
19073734 2009
3
Double-antigen enzyme-linked immunosorbent assay for detection of hepatitis E virus-specific antibodies in human or swine sera. 54 61
18495846 2008
4
Hepatitis E virus coinfection with hepatotropic viruses in Egyptian children. 61 54
18629421 2008
5
Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. 54 61
16447107 2006
6
The 41-amino-acid C-terminal region of the hepatitis E virus ORF3 protein interacts with bikunin, a kunitz-type serine protease inhibitor. 61 54
16140784 2005
7
Prevalence of hepatitis E virus in Egyptian children presented with minor hepatic disorders. 61 54
17977212 2005
8
Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) Is highly specific for diagnosis of acute HEV infection. 61 54
15634950 2005
9
Prevalence of antibodies to hepatitis E virus among Japanese blood donors: identification of three blood donors infected with a genotype 3 hepatitis E virus. 54 61
15221899 2004
10
The ORF3 protein of hepatitis E virus interacts with liver-specific alpha1-microglobulin and its precursor alpha1-microglobulin/bikunin precursor (AMBP) and expedites their export from the hepatocyte. 61 54
15037615 2004
11
Molecular and serological characterization of sporadic acute hepatitis E in a Japanese patient infected with a genotype III hepatitis E virus in 1993. 54 61
12560575 2003
12
Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M. 54 61
12204962 2002
13
Sero-epidemiology of hepatitis E virus (HEV) in urban and rural children of North India. 54 61
11359972 2001
14
Diagnostic value of immunoglobulin G (IgG) and IgM anti-hepatitis E virus (HEV) tests based on HEV RNA in an area where hepatitis E is not endemic. 54 61
11060044 2000
15
[Dynamics of anti-HEV ORF2, ORF3, IgM and IgG in serial sera of patients with hepatitis E and their clinical significance]. 61 54
10923456 1998
16
Role of immune serum globulins in pregnant women during an epidemic of hepatitis E. 54 61
9658374 1998
17
[Diagnosis of hepatitis E virus infection in sporadic acute hepatitis]. 54 61
15619831 1997
18
Acute sporadic hepatitis E virus infection in southern China. 61 54
8550986 1995
19
Changes of pre-S1 and pre-S2 antigens in sera of patients with hepatitis B virus infection. 54 61
2170220 1990
20
A systematic review of the epidemiology of Hepatitis E virus infection in South - Eastern Asia. 61
33372843 2021
21
Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response. 61
33583360 2021
22
Hepatitis E in Sub Saharan Africa - A significant emerging disease. 61
33204807 2021
23
Hepatitis E Infection in a Longitudinal Cohort of HCV and HCV/HIV Coinfected Persons. 61
33794657 2021
24
Hepatitis E virus and neurological manifestations. 61
33714454 2021
25
Acute CNS infections - Expanding the spectrum of neurological manifestations of hepatitis E virus? 61
33714083 2021
26
The origin of porcine endogenous retroviruses (PERVs). 61
33547957 2021
27
Virus-Host Cell Interplay during Hepatitis E Virus Infection. 61
32828646 2021
28
Hepatitis E-Associated Hospitalizations in the United States: 2010-2015 and 2015-2017. 61
33306246 2021
29
Seroprevalence of Hepatitis E Virus Infection among Blood Donors in Bulgaria. 61
33809748 2021
30
Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysis. 61
33301609 2021
31
Identification and a full genome analysis of novel camel hepatitis E virus strains obtained from Bactrian camels in Mongolia. 61
33662492 2021
32
Hepatitis E Virus in the Food of Animal Origin: A Review. 61
33784472 2021
33
Phylogeography and evolutionary history of hepatitis E virus genotype 3 in Argentina. 61
33739412 2021
34
Evidence for Independent Hepatitis E Virus Replication in the Brain. 61
33402526 2021
35
Epidemiology, diagnosis, vaccines, and bibliometric analysis of the 100 top-cited studies on Hepatitis E virus. 61
32755437 2021
36
Mitochondrial dysfunction and mitophagy pathway activation in hepatitis E virus-infected livers of Mongolian gerbils. 61
33684419 2021
37
Optimization and Implementation of the Virus Extraction Method for Hepatitis E Virus Detection from Raw Pork Liver. 61
33449335 2021
38
Characterization of a Cell Culture System of Persistent Hepatitis E Virus Infection in the Human HepaRG Hepatic Cell Line. 61
33806591 2021
39
IgG antibody response demonstrates inverse correlation with viral load in Bangladeshi women with acute hepatitis E virus genotype 1 infection. 61
33460834 2021
40
Seroprevalence of hepatitis E virus in risk populations and blood donors in a referral hospital in the south of Brazil. 61
33727656 2021
41
Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. 61
33683813 2021
42
Mobilization of γδ T Cells and IL-10 Production at the Acute Phase of Hepatitis E Virus Infection in Cytomegalovirus Carriers. 61
33483348 2021
43
Risk of hepatitis-E virus infections among blood donors in a regional blood transfusion centre in western India. 61
33738857 2021
44
The Foodborne Transmission of Hepatitis E Virus to Humans. 61
33738770 2021
45
Loss of antibodies to hepatitis E virus in organ transplant patients with hepatitis E. 61
33749100 2021
46
[Awareness of risk for transfusion reactions important for appropriate treatment]. 61
33720383 2021
47
Acute Hepatitis E in an immunocompromised patient with seropositive Rheumatoid Arthritis on rituximab and long-term methotrexate. 61
33783311 2021
48
Characterization of antibodies in human immunoglobulin products from different regions worldwide. 61
33524620 2021
49
Enterically transmitted hepatitis in the third millennium in northeastern Romania. 61
33603881 2021
50
Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis. 61
33034121 2021

Variations for Hepatitis E

Expression for Hepatitis E

Search GEO for disease gene expression data for Hepatitis E.

Pathways for Hepatitis E

Pathways related to Hepatitis E according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 TNF TLR3 ISG15 IFNG DDX58
2
Show member pathways
12.61 TNF TLR3 IFNG GRB2 FYN
3
Show member pathways
12.36 TNF IFNG GRB2 FYN CD40LG
4
Show member pathways
12.34 TNF ISG15 IFNL3 IFNG GRB2 FYN
5
Show member pathways
12.2 TNF IFNG GRB2 FYN CD40LG
6
Show member pathways
12.12 TNF TLR3 IFNG GRB2
7
Show member pathways
12.09 TNF IFNG F2 ALB
8
Show member pathways
12.09 TNF IFNG GRB2 FYN F2
9 11.87 TNF TLR3 IFNG DDX58 CD40LG
10 11.84 TNF TLR3 IFNG GRB2
11
Show member pathways
11.55 TNF TLR3 IFNG
12
Show member pathways
11.53 TNF IFNG CD40LG
13
Show member pathways
11.41 TNF IFNG CD40LG
14 11.24 TNF IFNG CD40LG

GO Terms for Hepatitis E

Cellular components related to Hepatitis E according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 TNF ISG15 IFNL3 IFNG HPX F2
2 extracellular space GO:0005615 9.36 TNF TLR3 MIR122 IFNL3 IFNG HPX
3 blood microparticle GO:0072562 9.26 HPX F2 AMBP ALB

Biological processes related to Hepatitis E according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.89 TNF GRB2 FYN F2
2 receptor-mediated endocytosis GO:0006898 9.84 HPX ASGR1 AMBP ALB
3 positive regulation of tumor necrosis factor production GO:0032760 9.79 TLR3 IFNG DDX58
4 positive regulation of interleukin-8 production GO:0032757 9.76 TNF TLR3 DDX58
5 positive regulation of cytokine production GO:0001819 9.75 TNF TLR3 IFNG
6 response to virus GO:0009615 9.73 TNF TLR3 IFNG DDX58
7 T cell costimulation GO:0031295 9.72 GRB2 FYN CD40LG
8 extrinsic apoptotic signaling pathway GO:0097191 9.7 TNF TLR3 IFNG
9 negative regulation of viral genome replication GO:0045071 9.69 TNF ISG15 IFNL3
10 positive regulation of interleukin-12 production GO:0032735 9.67 TLR3 IFNG CD40LG
11 positive regulation of chemokine production GO:0032722 9.65 TNF TLR3 IFNG
12 negative regulation of amyloid-beta clearance GO:1900222 9.61 TNF IFNG
13 regulation of immunoglobulin production GO:0002637 9.61 TNF CD40LG
14 necroptotic signaling pathway GO:0097527 9.6 TNF TLR3
15 microglial cell activation GO:0001774 9.58 TNF TLR3 IFNG
16 detection of virus GO:0009597 9.57 TLR3 DDX58
17 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.56 TNF HPX
18 positive regulation of interleukin-6 production GO:0032755 9.56 TNF TLR3 IFNG DDX58
19 defense response to virus GO:0051607 9.55 TLR3 ISG15 IFNL3 IFNG DDX58
20 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 TNF IFNG
21 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 TNF IFNG
22 positive regulation of nitrogen compound metabolic process GO:0051173 9.32 TNF IFNG
23 viral process GO:0016032 9.28 TSG101 TMEM134 ISG15 HPX GRB2 FYN
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.26 TNF IFNG HPX FYN

Molecular functions related to Hepatitis E according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IFNL3 IFNG CD40LG

Sources for Hepatitis E

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....